Who are Statins with or without ezetimibe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, Lescol, FLUVASTATIN SODIUM, HMG CoA inhibitor, Statin (simvastatin).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/statins-with-or-without-ezetimibe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Statins with or without ezetimibe — Competitive Intelligence Brief

Statins with or without ezetimibe (Statins with or without ezetimibe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA reductase inhibitor. Area: Cardiovascular.

phase 3 HMG-CoA reductase inhibitor HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Statins with or without ezetimibe (Statins with or without ezetimibe) — Beijing Anzhen Hospital. Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, while ezetimibe inhibits the absorption of cholesterol in the small intestine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Statins with or without ezetimibe TARGET	Statins with or without ezetimibe	Beijing Anzhen Hospital	phase 3	HMG-CoA reductase inhibitor	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
HMG CoA inhibitor	HMG CoA inhibitor	AstraZeneca	marketed	Statin (HMG-CoA reductase inhibitor)	HMG-CoA reductase
Statin (simvastatin)	Statin (simvastatin)	University of Aarhus	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (HMG-CoA reductase inhibitor class)

Beijing Anzhen Hospital · 1 drug in this class
Boryung Pharmaceutical Co., Ltd · 1 drug in this class
Jeil Pharmaceutical Co., Ltd. · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Statins with or without ezetimibe — Competitive Intelligence Brief. https://druglandscape.com/ci/statins-with-or-without-ezetimibe. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab